CompletedNot Applicable

Sarcoidosis Immunotsuppressive Therapy and Lymphoma Development

Egypt40 participantsStarted 2025-08-01

Plain-language summary

Impact of Immunosuppressive Therapy for Sarcoidosis on Lymphoma Development

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Inclusion criteria include adult patients (≥18 years) with histologically confirmed sarcoidosis, receiving or planned to receive immunosuppressive therapy Exclusion Criteria:Patients with a prior history of lymphoma or other active malignancy, HIV infection, or other primary immunodeficiency will be excluded. \-

What they're measuring

The primary outcome will be incident, biopsy-proven lymphoma during the 12-month follow-up.

Timeframe: 12 MONTHS

lymphoma development

Timeframe: 12 months

Trial details

NCT IDNCT07343401

SponsorAlexandria University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-12-30

View on ClinicalTrials.gov More Sarcoidosis Lung trials